BioCryst is shutting down internal drug discovery and closing its Birmingham, AL research site, cutting 2026 opex guidance to $420–$440M while continuing work on navenibart and BCX17725.
BioCryst Pharmaceuticals is winding down its own drug discovery work, saying that it plans to look for future drug programs externally.
The company
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Zymeworks acquires struggling Theravance for $929M
BridgeBio attracts $1B in equity for new launches, but analyst smells M&A ‘dry powder’
FDA rejects Sobi’s gout drug over manufacturing issues, sparing Amgen blockbuster
Correction: Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI
AlzeCure Pharma Enters an Out-Licensing and Collaboration Agreement with QuantumCell ApS for the NeuroRestore ACD856 Project
Biogen pauses or cancels most R&D programs from its $5.6B Apellis buyout and lays off staff, keeping its focus on Empaveli and…
Fulcrum Therapeutics cuts 84% of staff after halting sickle cell drug; Seres extends cash runway to Q1 2027 via $25M Nestlé deal.
Four months after Theravance Biopharma shut down its R&D unit, laid | Four months after Theravance Biopharma shut down its R&D…
Bioanalytical laboratories are highly strategic and there are only three of note in Australia, including Genesis Capital-owned…
Bristol Myers Squibb looks to Texas; Novartis looks to remove CDMO from its Slovenia campus; and more
Fulcrum Therapeutics is scrapping its sole clinical-stage medicine, pociredir for sickle cell disease, after feedback from the…
